Evidence map›Paper›PMID 41775949›Full record

ArticleIndian journal of pediatrics2026

Assessing the Impact of Rituximab on Treatment Outcomes in Pediatric Advanced Mature B-Non Hodgkin Lymphoma.

Ekta Rahul, Archana Sasi, Shuvadeep Ganguly, Vivek Kumar, Deepam Pushpam, Atul Batra, Saumyaranjan Mallick, Mehar Chand Sharma, Rakesh Kumar, Sameer Bakhshi

Abstract read
PubMed Publisher
In one paragraph

Article in Indian journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ekta Rahul *Department of Pathology, All India Institute of Medical Sciences CAPFIMS, Maidangarhi, New Delhi, India.
Archana Sasi *Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Shuvadeep GangulyDepartment of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.
Vivek KumarDepartment of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Deepam PushpamDepartment of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Atul BatraDepartment of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Saumyaranjan MallickDepartment of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Mehar Chand SharmaDepartment of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Rakesh KumarDepartment of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.
Sameer BakhshiDepartment of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India. sambakh@hotmail.com.ORCID 0000-0001-9367-4407

Funding

Indian Council of Medical Research 5/13/2/TF/NHL/2023/NCD-III
6 · The paper itself

Abstract

objectivesTo assess the impact of adding rituximab on outcomes in children with aggressive mature B-non Hodgkin’s lymphoma (B-NHL) in resource-challenged settings.

methodsThis retrospective study was conducted at a tertiary care cancer center in India. Children aged < 18 y with newly diagnosed advanced mature B-NHL between January 2004-June 2023 were included. Patients treated in December 2016 or after were included in the post-rituximab group and those treated prior were included in the pre-rituximab group. Clinical details were compiled from hospital records. Patients in the pre- and post-rituximab groups were matched using 1:1 propensity score matching to minimize baseline differences. The impact of rituximab on event-free survival (EFS) and overall survival (OS) was examined using multivariable Cox proportional hazards regression on the matched cohort.

resultsThe cohort included 138 patients in the pre-rituximab and 82 in the post-rituximab groups of median age eight years. The 5-year EFS was 56.7% and 69.6% in the pre- and post-rituximab groups respectively and treatment-related mortality was similar in both groups (17.4% and 17.3% respectively; p = 0.952). Rituximab use predicted for superior EFS (aHR = 0.30; 95% CI: 0.14–0.67; p = 0.003) and OS (aHR = 0.29; 95% CI = 0.12–0.70; p = 0.006) following adjustment for baseline characteristics. In a 1:1 propensity score-matched cohort, patients in the post-rituximab group had superior 5-year EFS (HR = 0.20, p = 0.0014) and OS (HR = 0.27, p = 0.016).

conclusionsThe present data suggests that rituximab addition improves survival in children with aggressive advanced mature B-NHL, even in low-middle income country (LMIC) settings without an increase in treatment-related mortality.

Indexed as

Antineoplastic Agents, ImmunologicalLymphoma, B-CellLymphoma, Non-HodgkinRituximabAdolescentChildChild, PreschoolFemaleHumansIndiaMaleRetrospective StudiesTreatment OutcomeAntineoplastic Agents, ImmunologicalRituximabChildhood cancerLow-middle income countryNon-Hodgkin lymphomaRituximabTreatment outcomes

Identifiers

PMID41775949

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.